Intellia Therapeutics, Inc. (NTLA) Stock Profile & Financial OverviewIntellia Therapeutics, Inc.
NTLA Company Overview & Business Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key Information
Current Trend for NTLA
An assessment of the current trend environment for NTLA, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for NTLA is a Sideways Consolidation (Range-Bound Environment).
The weekly trend is in a consolidation regime, which automatically downgrades the daily signal to sideways conditions. This environment favors short-term mean-reversion rather than trend-following.
- The weekly context is non-trending (sideways), which typically caps the duration and magnitude of daily trend moves.
- Price is currently compressing tightly (optimal low-risk zone), sitting 0.43 ATR away from the adaptive KAMA baseline.
- The current market structure is holding within recent defined ranges.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, NTLA in a non-directional consolidation; Long-term trend is bullish.
Trend Strength: NTLA last closed at 9.59, trading 0.6 ATR above the adaptive KAMA baseline (9.15). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Risk indicators: No active structural constraints identified.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 9.59, KAMA 9.15.